论文部分内容阅读
目的:探讨沐舒坦对呼吸系统的保护作用及其机制。方法:选择我院2009年6月至2011年12月收治的呼吸系统疾病患者80例,随机分为两组,对照组40例采用常规抗生素及吸氧治疗,观察组40例在此基础上加用沐舒坦治疗,就两组的临床资料进行回顾性分析。结果:观察组总有效率为97.5%,对照组总有效率为77.5%。观察组显著高于对照组,差异有统计学意义(P<0.05)。两组均无严重不良反应发生。结论:采用沐舒坦治疗呼吸系统疾病,具有一定的安全性和有效性,明显改善了患者的生存质量。
Objective: To explore the protective effect of mucosolvan on respiratory system and its mechanism. Methods: Eighty patients with respiratory diseases admitted from June 2009 to December 2011 in our hospital were randomly divided into two groups. In the control group, 40 patients were treated with conventional antibiotics and oxygen therapy. In the observation group of 40 patients, With mucosolvan treatment, the clinical data of two groups were retrospectively analyzed. Results: The total effective rate was 97.5% in the observation group and 77.5% in the control group. The observation group was significantly higher than the control group, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: The treatment of respiratory diseases with mucosolvan has certain safety and effectiveness, and obviously improves the quality of life of patients.